Neuropathology of genetically engineered mice: Consensus report and recommendations from an international forum

被引：44

作者：

Weiss W.A. ^{[1
,2
,3
,6
]}

Israel M. ^{[4
,5
]}

Cobbs C. ^{[7
]}

Holland E. ^{[8
,9
,10
]}

James C.D. ^{[11
]}

Louis D.N. ^{[12
]}

Marks C. ^{[13
]}

McClatchey A.I. ^{[14
]}

Roberts T. ^{[15
]}

Van Dyke T. ^{[16
]}

Wetmore C. ^{[17
]}

Chiu I.-M. ^{[18
]}

Giovannini M. ^{[19
]}

Guha A. ^{[20
]}

Higgins R.J. ^{[21
]}

Marino S. ^{[22
]}

Radovanovic I. ^{[23
]}

Reilly K. ^{[24
]}

Aldape K. ^{[25
]}

机构：

[1] Department of Neurology, University of California, San Francisco, CA 94143-0114

[2] Department of Pediatrics, University of California, San Francisco, CA 94143-0114

[3] Department of Neurological Surgery, University of California, San Francisco, CA 94143-0114

[4] Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, One Medical Drive

[5] Department of Genetics, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, One Medical Drive

[6] Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, One Medical Drive

[7] University of Alabama at Birmingham, Department of Surgery, Division of Neurosurgery, Birmingham, AL 35294, 1813 6th Avenue South

[8] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, Hilton Building

[9] Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York

[10] Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021

[11] Department of Cell Biology, Memorial Sloan Kettering Cancer Center, New York

[12] Department of Pathology, Neurosurgical Service and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston

[13] Division of Cancer Biology, National Cancer Institute, Bethesda

[14] MGH Cancer Center, Department of Pathology, Harvard Medical School, Charlestown, MA 02129, Building 149

[15] Department of Medical Imaging, University of Toronto, Toronto, ON M5S 3E2, Fitzgerald Building

[16] 1612-044 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599

[17] Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic and Cancer Center, Rochester, MN 55905

[18] Department of Internal Medicine, Ohio State University, Columbus, OH 43210

[19] INSERM U434, Fondation Jean Dausset - CEPH, 75010 Paris

[20] Department of Surgery (Neurosurgery), Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, 3017 McMaster Bld

[21] Department of Pathology, Microbiology and Immunology, University of California, Davis, CA 95616

[22] Institute of Neuropathology, University Hospital, CH-8091 Zurich

[23] Institute of Clinical Pathology, University Hospital, CH-8091 Zurich

[24] MIT/Center for Cancer Research, Cambridge, MA 02139, Building E17-518

[25] Department of Pathology, Brain Tumor Center, UT-MD Anderson Cancer Center, Houston, TX 77030

来源：

Oncogene | 2002年 / 21卷 / 49期

关键词：

Genetically engineered mice; Mouse brain tumor models; Mouse nerve sheath tumor models; Neuropathological evaluation;

D O I：

10.1038/sj.onc.1205936

中图分类号：

学科分类号：

摘要：

The Mouse Models of Cancer Consortium of the NCI sponsored a meeting of neuropathologists and veterinary pathologists in New York City in November of 2000. A rapidly growing number of genetically engineered mice (GEM) predisposed to tumors of the nervous system have led to a concomitant need for neuropathological evaluation and validation of these models. A panel of 13 pathologists reviewed material representing most of the available published and unpublished GEM models of medulloblastoma, primitive neuroectodermal tumor, astrocytoma, oligodendroglioma, mixed glioma, and tumors of the peripheral nerve. The GEM tumors were found to have many similarities and some distinct differences with respect to human disease. After review of the biology and pathology for all models presented, participants were split into groups reflective of clinical expertise in human pathology, tumor biology, neuroimaging, or treatment/intervention. Recommendations were made detailing an extensive and complete neuropathological characterization of animals. Importance was placed on including information on strains, tumor clonality, and examination for genetic mutation or altered gene expression characteristics of the corresponding human malignancy. Specific proposals were made to incorporate GEM models in emerging neuroradiological modalities. Recommendations were also made for preclinical validation of these models in cancer therapeutics, and for incorporation of surrogate markers of tumor burden to facilitate preclinical evaluation of new therapies.

引用

页码：7453 / 7463

页数：10

共 42 条

[1]

Bajenaru M.L., Donahoe J., Corral T., Reilly K.M., Brophy S., Pellicer A., Gutmann D.H., Glia, 33, pp. 314-323, (2001)

[2]

Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H., Mol. Cell. Biol., 22, pp. 5100-5113, (2002)

[3]

Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A., Louis D.N., J. Natl. Cancer Int., 90, pp. 1473-1479, (1998)

[4]

Chiu I.M., Touhalisky K., Liu Y., Yates A., Frostholm A., Oncogene, 19, pp. 6229-6239, (2000)

[5]

Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Bronson R.T., Jacks T., Science, 286, pp. 2172-2167, (1999)

[6]

Dai C., Celestino J.C., Okada Y., Louis D.N., Fuller G.N., Holland E.C., Genes Dev., 15, pp. 1913-1925, (2001)

[7]

Di Rocci F., Carroll R.S., Zhang J., Black P.M., Neurosurgery, 42, pp. 341-346, (1998)

[8]

Ding H., Roncari L., Shannon P., Wu X., Lau N., Karaskova J., Gutmann D.H., Squire J.A., Nagy A., Guha A., Cancer Res., 61, pp. 3826-3836, (2001)

[9]

Fortin D., Cairncross G.J., Hammond R.R., Neurosurgery, 45, pp. 1279-1291, (1999)

[10]

Garcea R.L., Dis. Markers, 17, pp. 149-151, (2001)

← 1 2 3 4 5 →